News and Trends 24 Nov 2022 AI works on artificial DNA for future drug development …The researchers have developed their method in the yeast Saccharomyces cerevisiae, whose cells resemble mammalian cells. The next step is to use human cells. The researchers hope their progress will… November 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 28 May 2025 Myasthenia gravis treatments: what’s on the horizon? …Cartesian Therapeutics’ Descartes-08 is an autologous mRNA CAR-T cell therapy, meaning that it uses a patient’s own T cells that have been modified with mRNA to help them better target… May 28, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Cleara Biotech closes $2.5M seed financing round to progress senescence treatment Cleara Biotech has closed a $2.5 million seed financing round that it will use for progress its compounds toward clinical development. The company that develops therapies for treating different pathologies… September 28, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 BiVictriX announces positive data from leukemia study …and provide further evidence that our first-in-class platform offers the potential to deliver the next generation of highly selective, anti-cancer therapies. Generating data that demonstrates BVX001 was well-tolerated in this… January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Human Immunology Biosciences launches with $120M …and therapeutic engineering. This discovery toolkit leverages emerging insights from research and development efforts to profile the immune phenotypes that drive IMDs. The toolkit will allow HI-Bio to rapidly advance… November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2025 Top biotech deals of March 2025 …in an all-cash transaction, according to a press release. The two have cooperated together over the years to develop and commercialize Abecma, a CAR-T cell therapy for multiple myeloma, which… April 2, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Sep 2025 Budget blues: where are cell and gene therapies heading? …T-cell therapy by downregulating the specific antigen that the CAR T-cells are programmed to recognize and attack. This makes the CAR T-cells ineffective, leading to cancer relapse. As for on-target… September 17, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Nov 2024 Cystic fibrosis: Five biotechs breathing life into the therapeutic space …dry powder. The nebulized version of the drug is what is being evaluated to treat cystic fibrosis. The drug works by blocking the sodium channel (ENaC) in the cells that… November 7, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Jan 2024 Eight newly approved drugs that could become blockbusters in 2024 …represses fetal hemoglobin, the therapy restarts the production of the protein in order to boost oxygen supply to the tissues. But how exactly is the therapy administered? Stem cells from… January 22, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Startup Scout 21 Nov 2022 Osivax is designing future-proof influenza and Covid vaccines …T cells must often be tested in tissue samples. “If you can get an antibody-based vaccine that protects well and neutralizes the virus, you wouldn’t need to care that much… November 21, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jun 2019 The 10 Biotech Companies in London to Keep an Eye on in 2019 …on the development of next-generation CAR-T therapy. The company aims to reduce the life-threatening side effects of this kind of treatment by killing cancer cells without affecting the healthy T… June 10, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2017 UK Immunotherapy Biotech raises Massive Funding in Series C …the company is currently exploring the use of allogeneic, ‘off-the-shelf’, Natural Killer T (NKT) cells to target the ‘hard-to-crack’ solid tumors. The funds will also allow Cell Medica to enter… March 16, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email